Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma

H. Miles Prince, Nizar J. Bahlis, Paula Rodríguez-Otero, Lionel Karlin, Luke Akard, Asya Varshavsky-Yanovsky, Michael P. Chu, Yuya Nagai, David H. Vesole, Anne Hickman, Sharon T. Sullivan, Eric Leip, Umberto Conte, Andrea Viqueira, Alexander M. Lesokhin

Blood (2024) 144 (Supplement 1): 4738.

https://doi.org/10.1182/blood-2024-208192

Published: 2024

Journal Articles

Impact of Publicly Reported Center Specific Analysis on Patient Selection Practices for Hematopoietic Stem Cell Transplantation

Christopher Strouse, Mark Juckett, Brent R. Logan, Noel Estrada-Merly, Jaime M. Preussler, Tony Truong, Jesse Troy, Nandita Khera, William Wood, Hemalatha G. Rangarajan, Luke Akard, Neel S. Bhatt, Akshay Sharma, Wael Saber

Blood (2023) 142 (Supplement 1): 373.

https://doi.org/10.1182/blood-2023-182013

Published: 2023

Journal Articles

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

Andres Forero-Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub, Michael S. Wertheim, William J. Edenfield, Paolo Caimi, Martin Gutierrez, Luke Akard, Carolina Escobar, Justin Call, Daniel Persky, Swaminathan Iyer, Douglas J. DeMarini, Li Zhou, Xuejun Chen, Fitzroy Dawkins, Tycel J. Phillips

Blood (2019) 133 (16): 1742–1752.

https://doi.org/10.1182/blood-2018-08-867499

Published: 2019

Includes: Supplemental data

Journal Articles

Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)

Andres Forero-Torres, MD, Rod Ramchandren, MD, Abdulraheem Yacoub, MD, Michael S. Wertheim, MD, William J. Edenfield, MD, Paolo Caimi, MD, Martin Gutierrez, MD, Luke Akard, MD, Carolina Escobar, MD, Justin Call, MD, Daniel Persky, MD, Swami P. Iyer, MD, Douglas J. DeMarini, PhD, Li Zhou, PhD, Swamy Yeleswaram, PhD, Tycel J. Phillips, MD

Blood (2017) 130 (Supplement 1): 410.

https://doi.org/10.1182/blood.V130.Suppl_1.410.410

Published: 2017

Journal Articles

Phase 1 Clinical Investigation of Human Myeloid Progenitor Cells (CLT-008) As a Supportive Care Measure during Chemotherapy for Acute Myeloid Leukemia (AML)

Matthew J. Wieduwilt, MD PhD, Jan Cerny, MD PhD, Luke Akard, MD, Celalettin Ustun, MD, Farhad Ravandi, MD, James M. Rossetti, DO, Brian T. Hill, MD PhD, Janice (Wes) Brown, MD, Lois Kellerman, Rod Van Syoc, William Reed, MD, Charalambos Andreadis, MD MSCE

Blood (2014) 124 (21): 2268.

https://doi.org/10.1182/blood.V124.21.2268.2268

Published: 2014

Journal Articles

Why Don't Hematologists Follow Chronic Myeloid Leukemia Monitoring Guidelines? A Survey Of Practioners In New Jersey and Indiana

Stuart Goldberg, MD, Luke Akard, MD

Blood (2013) 122 (21): 5187.

https://doi.org/10.1182/blood.V122.21.5187.5187

Published: 2013

Journal Articles

Blast Phase Chronic Myeloid Leukemia: A Pooled Analysis of Subcutaneous Omacetaxine Mepesuccinate in Treatment-Resistant Patients

H. Jean Khoury, MD, Jorge E. Cortes, MD, Meir Wetzler, MD, Jeffrey H. Lipton, MD, PhD, Michele Baccarani, MD, Dan Douer, MD, Adam Craig, MD, PhD, Hagop M. Kantarjian, MD, Luke Akard, MD

Blood (2012) 120 (21): 3753.

https://doi.org/10.1182/blood.V120.21.3753.3753

Published: 2012

Journal Articles

Change in Chronic Low-Grade Nonhematologic Adverse Events (AEs) and Quality of Life (QoL) in Adult Patients (pts) with Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Switched From Imatinib (IM) to Nilotinib (NIL)

Jorge E. Cortes, MD, Jeffrey H. Lipton, MD, PhD, Carole B. Miller, MD, Sikander Ailawadhi, MD, Luke Akard, MD, Javier Pinilla-Ibarz, MD, PhD, Felice P. Lin, PharmD, Solveig G. Ericson, MD, PhD, Michael J. Mauro, MD

Blood (2012) 120 (21): 3782.

https://doi.org/10.1182/blood.V120.21.3782.3782

Published: 2012

Journal Articles

Long-Term Follow-up of Ongoing Patients in 2 Studies of Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.

Hagop M. Kantarjian, MD, Jeffrey H. Lipton, MD, PhD, Michele Baccarani, MD, Franck E. Nicolini, MD, PhD, Meir Wetzler, MD, Luke Akard, MD, Laurence Legros, MD, PhD, Krzysztof Warzocha, Adam Craig, MD, PhD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 2787.

https://doi.org/10.1182/blood.V120.21.2787.2787

Published: 2012

Journal Articles

Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study

Tim H Brümmendorf, Hagop M. Kantarjian, MD, Carlo Gambacorti-Passerini, Francois Guilhot, Luke Akard, MD, Vaishali Doshi, Jeff H Lipton, MD, Dmitri Pavlov, Karin Gogat, Ladan Duvillie, Mark Shapiro, Jorge E Cortes, MD

Blood (2012) 120 (21): 69.

https://doi.org/10.1182/blood.V120.21.69.69

Published: 2012

Journal Articles

Associations Between Baseline Mutation Status and Response to Treatment with Omacetaxine Mepesuccinate in Heavily Pretreated Patients with Chronic Myeloid Leukemia

Jeffrey H. Lipton, MD, PhD, Franck E. Nicolini, MD, PhD, Meir Wetzler, MD, Luke Akard, MD, Michele Baccarani, MD, Hagop M. Kantarjian, MD, Adam Craig, MD, PhD, Jorge E Cortes, MD

Blood (2012) 120 (21): 4433.

https://doi.org/10.1182/blood.V120.21.4433.4433

Published: 2012

Journal Articles

A Phase II Study of Oral Panobinostat (LBH589) in Accelerated Phase (AP) or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Patients Resistant to ≥2 BCR-ABL Tyrosine Kinase Inhibitors

François Guilhot, Viviane Dubruille, Aleksander B. Skotnicki, Andrey Hellmann, Jila Shamsazar, Priscille M. Bourquelot, Muhammad Jalaluddin, Martha Li, Elisabetta Abruzzese, Luke Akard

Blood (2008) 112 (11): 4263.

https://doi.org/10.1182/blood.V112.11.4263.4263

Published: 2008

NARROW

MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma

Impact of Publicly Reported Center Specific Analysis on Patient Selection Practices for Hematopoietic Stem Cell Transplantation

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)

Phase 1 Clinical Investigation of Human Myeloid Progenitor Cells (CLT-008) As a Supportive Care Measure during Chemotherapy for Acute Myeloid Leukemia (AML)

Why Don't Hematologists Follow Chronic Myeloid Leukemia Monitoring Guidelines? A Survey Of Practioners In New Jersey and Indiana

Blast Phase Chronic Myeloid Leukemia: A Pooled Analysis of Subcutaneous Omacetaxine Mepesuccinate in Treatment-Resistant Patients

Change in Chronic Low-Grade Nonhematologic Adverse Events (AEs) and Quality of Life (QoL) in Adult Patients (pts) with Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Switched From Imatinib (IM) to Nilotinib (NIL)

Long-Term Follow-up of Ongoing Patients in 2 Studies of Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.

Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study

Associations Between Baseline Mutation Status and Response to Treatment with Omacetaxine Mepesuccinate in Heavily Pretreated Patients with Chronic Myeloid Leukemia

A Phase II Study of Oral Panobinostat (LBH589) in Accelerated Phase (AP) or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Patients Resistant to ≥2 BCR-ABL Tyrosine Kinase Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only